Notice2021-20925
Solicitation of Nominations for Appointment to the Clinical Laboratory Improvement Advisory Committee (CLIAC)
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 27, 2021
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC) is seeking nominations for membership on the CLIAC. The CLIAC consists of 20 experts including the Chair, represents a diverse membership across laboratory specialties, professional roles (laboratory management, technical specialists, physicians, nurses) and practice settings (academic, clinical, public health), and includes a consumer representative.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 184 (Monday, September 27, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 184 (Monday, September 27, 2021)]
[Notices]
[Pages 53312-53313]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-20925]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Appointment to the Clinical
Laboratory Improvement Advisory Committee (CLIAC)
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) is
seeking nominations for membership on the CLIAC. The CLIAC consists of
20 experts including the Chair, represents a diverse membership across
laboratory specialties, professional roles (laboratory management,
technical specialists, physicians, nurses) and practice settings
(academic, clinical, public health), and includes a consumer
representative.
DATES: Nominations for membership on CLIAC must be received no later
than March 1, 2022. Packages received after this time will not be
considered for the current membership cycle.
ADDRESSES: All nominations should be mailed to Nancy Anderson, MMSc,
MT(ASCP), CLIAC Secretary, Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
[[Page 53313]]
for Surveillance, Epidemiology and Laboratory Services, Office of
Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4018, Telephone: (404) 498-2741; or via email at <a href="/cdn-cgi/l/email-protection#88cbc4c1c9cbc8ebeceba6efe7fe"><span class="__cf_email__" data-cfemail="4a0906030b090a292e29642d253c">[email protected]</span></a>.
FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Deputy Chief,
Quality and Safety Systems Branch, Division of Laboratory Systems,
Center for Surveillance, Epidemiology and Laboratory Services, Office
of Public Health Scientific Services, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia
30329-4018, Telephone: (404) 498-2769; <a href="/cdn-cgi/l/email-protection#1c544f687d727b5c7f787f327b736a"><span class="__cf_email__" data-cfemail="1b53486f7a757c5b787f78357c746d">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The Committee includes three ex officio
members (or designees), including the Director, CDC; the Administrator,
Centers for Medicare & Medicaid Services (CMS); and the Commissioner,
Food and Drug Administration (FDA). A nonvoting representative from the
Advanced Medical Technology Association (AdvaMed) serves as the
industry liaison. The Designated Federal Official (DFO) or their
designee and the Executive Secretary are present at all meetings to
ensure meetings are within applicable statutory, regulatory, and HHS
General Administration manual directives.
Nominations are being sought for individuals who have the expertise
and qualifications necessary to contribute to the accomplishments of
the committee's objectives. Nominees will be selected based on
expertise in the fields of microbiology (including bacteriology,
mycobacteriology, mycology, parasitology, and virology), immunology
(including histocompatibility), chemistry, hematology, pathology
(including histopathology and cytology), or genetic testing (including
cytogenetics); from representatives in the fields of medical
technology, bioinformatics, public health, and clinical practice; and
from consumer representatives. Federal employees will not be considered
for membership. Members may be invited to serve for up to four-year
terms.
Selection of members is based on candidates' qualifications to
contribute to the accomplishment of CLIAC objectives (<a href="https://www.cdc.gov/cliac/">https://www.cdc.gov/cliac/</a>).
The U.S. Department of Health and Human Services policy stipulates
that committee membership be balanced in terms of points of view
represented, and the committee's function. Appointments shall be made
without discrimination on the basis of age, race, ethnicity, gender,
sexual orientation, gender identity, HIV status, disability, and
cultural, religious, or socioeconomic status. Nominees must be U.S.
citizens, and cannot be full-time employees of the U.S. Government.
Current participation on federal workgroups or prior experience serving
on a federal advisory committee does not disqualify a candidate;
however, HHS policy is to avoid excessive individual service on
advisory committees and multiple committee memberships. Committee
members are Special Government Employees (SGEs), requiring the filing
of financial disclosure reports at the beginning and annually during
their terms. CDC reviews potential candidates for CLIAC membership each
year and provides a slate of nominees for consideration to the
Secretary of HHS for final selection. HHS notifies selected candidates
of their appointment near the start of the term in July, or as soon as
the HHS selection process is completed. Note that the need for
different expertise varies from year to year and a candidate who is not
selected in one year may be reconsidered in a subsequent year.
Candidates should submit the following items:
[ssquf] Current curriculum vitae, including complete contact
information (telephone numbers, mailing address, email address).
[ssquf] At least one letter of recommendation from person(s) not
employed by the U.S. Department of Health and Human Services.
(Candidates may submit letter(s) from current HHS employees if they
wish, but at least one letter must be submitted by a person not
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
Nominations may be submitted by the candidate, or by the person/
organization recommending the candidate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-20925 Filed 9-24-21; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 27, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.